Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MDC 917

Known as: MDC-917, MDC917 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Phospho‐ibuprofen (MDC‐917) incorporated in nanocarriers: anti‐cancer activity in vitro and in vivo
Phospho‐ibuprofen (P‐I; MDC‐917) inhibits the growth of colon cancer in mice. Here, we investigated the use of nanocarriers to… Expand
2012
2012
Regioselective oxidation of phospho‐NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety
Phospho‐ibuprofen (MDC‐917) and phospho‐sulindac (OXT‐328) are highly effective in cancer and arthritis treatment in preclinical… Expand
2011
2011
The novel phospho‐non‐steroidal anti‐inflammatory drugs, OXT‐328, MDC‐22 and MDC‐917, inhibit adjuvant‐induced arthritis in rats
BACKGROUND AND PURPOSE The use of non‐steroidal anti‐inflammatory drugs (NSAIDs) in the treatment of rheumatoid arthritis (RA) is… Expand
2011
2011
Phospho-Ibuprofen (MDC-917) Is a Novel Agent against Colon Cancer: Efficacy, Metabolism, and Pharmacokinetics in Mouse Models
  • G. Xie, Y. Sun, +5 authors B. Rigas
  • Journal of Pharmacology and Experimental…
  • 2011
    • Corpus ID: 27243255
We have developed a novel chemical modification of conventional nonsteroidal anti-inflammatory drugs to reduce their toxicity and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Phospho-ibuprofen (MDC-917) suppresses breast cancer growth: an effect controlled by the thioredoxin system
IntroductionWe have recently synthesized phospho-ibuprofen (P-I; MDC-917), a safer derivative of ibuprofen, which has shown anti… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Sterically Stabilized Liposomes Incorporating the Novel Anticancer Agent Phospho-Ibuprofen (MDC-917): Preparation, Characterization, and In Vitro/In Vivo Evaluation
ABSTRACTPurposeTo incorporate phospho-ibuprofen (P-I), a lipophilic, water insoluble novel anti-cancer agent, into pegylated… Expand
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE